Global BET Inhibitors Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

  • ID: 4340248
  • Report
  • Region: Global
  • 116 pages
  • P&S Market Research
1 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Resverlogix Corp
  • MORE
Bromodomain and extra-terminal (BET) inhibitors are small molecule inhibitors including bromodomain 2 (BRD2), bromodomain 3 (BRD3), bromodomain 4 (BRD4) and bromodomain testis (BRDT), which have anti-proliferating properties. These targets of inhibitors are supposed to bind with myc gene, which is a most desired target for cancer therapeutics. BET inhibitors are first-in-class targeted therapies that directly target bromodomain proteins to deliver a new therapeutic prospect as inhibition of epigenetic regulators.

BET inhibitor constitutes that class of drugs that prevents interactions between BET proteins, and transcription factors and acetylated histone. This results in immunosuppressive and anti-cancer properties of BET inhibitor. BET inhibitors when administered, bind to acetylated lysine motifs, thus, preventing interaction between acetylated lysine and BET proteins. This disrupts the gene expression and chromatin remodeling. Inhibition of certain growth promoting genes results in reducing tumor cell growth. BET proteins play an important role in cell growth and development as transcriptional regulators. Inhibition of BET proteins offered a new therapeutic approach for the treatment of cancer, cardiovascular diseases and other diseases.

The discovery of BET proteins shows that they play a crucial role in transcriptional activation, and thus, have oncogenic potential. This has resulted in the development of several small molecule BET inhibitors. Preclinical studies have shown promising results for many indications, both in in-vitro and in-vivo studies. There are many early phase clinical trials for these inhibitors that are presently testing the efficacy of BET inhibitors.

Competitive Landscape

Some of the key players developing BET inhibitors are Resverlogix Corp., GlaxoSmithKline plc, Bristol-Myers Squibb Company and others.

Scope for Customization

Customization is offered as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

- Market Forecast - Market analysis and forecast for the drug candidates in the latest stage of development
- Company Profiles - Wider company coverage in terms of detailed analysis or additional company profiles

Market Segementation:

The research offers pipeline analysis as of 2017, to estimate and analyze the emerging therapies and their progress status in different research and development phases. The report also contains competitive analysis and extensive information on monotherapies, combination therapies, targets and mechanism of action, and drug origin with relevance to all key therapy areas in the pharmaceutical industry.

BET Inhibitors Pipeline Analysis:

- By target
- By route of administration
- By company
- By phase
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline plc
  • Resverlogix Corp
  • MORE

1. Research Background
1.1. Research Objectives
1.2. Definition
1.3. Research Scope
1.3.1. Pipeline Analysis by Phase
1.3.2. Pipeline Analysis by Route of Administration
1.3.3. Pipeline Analysis by Molecule Type
1.4. Key Stakeholders

2. Research Methodology
2.1. Secondary Research
2.2. Primary Research
2.2.1. Breakdown of Primary Research Respondents
2.2.1.1. By industry participants
2.2.1.2. By company type

3. Executive Summary

4. Pipeline Outlook
4.1. BET Inhibitors Overview
4.2. Key Drivers
4.3. Key Barriers
4.4. BET Inhibitors Pipeline Analysis
4.4.1. Pipeline Analysis by Phase
4.4.2. Pipeline Analysis by Molecule Type
4.4.3. Pipeline Analysis by Route of Administration
4.4.4. Pipeline Analysis by Company

5. BET Inhibitors Pipeline Analysis by Phase (2017)
5.1. Pre-registration/Registration: Drug Profiles
5.1.1. Pre-Clinical Studies
5.1.2. Clinical Trials
5.1.3. Clinical Results
5.1.4. Strategic Developments
5.1.5. Designations
5.1.6. Grants
5.1.7. Patents
5.1.8. Technology
5.2. Phase III: Drug Profiles
5.2.1. Pre-Clinical Studies
5.2.2. Clinical Trials
5.2.3. Clinical Results
5.2.4. Strategic Developments
5.2.5. Designations
5.2.6. Grants
5.2.7. Patents
5.2.8. Technology
5.3. Phase II: Drug Profiles
5.3.1. Pre-Clinical Studies
5.3.2. Clinical Trials
5.3.3. Clinical Results
5.3.4. Strategic Developments
5.3.5. Designations
5.3.6. Grants
5.3.7. Patents
5.3.8. Technology
5.4. Phase I: Drug Profiles
5.4.1. Pre-Clinical Studies
5.4.2. Clinical Trials
5.4.3. Clinical Results
5.4.4. Strategic Developments
5.4.5. Designations
5.4.6. Grants
5.4.7. Patents
5.4.8. Technology
5.5. Pre-Clinical: Drug Profiles
5.5.1. Pre-Clinical Studies
5.5.2. Strategic Developments
5.5.3. Designations
5.5.4. Grants
5.5.5. Patents
5.5.6. Technology
5.6. Discovery: Drug Profiles
5.6.1. Strategic Developments
5.6.2. Designations
5.6.3. Grants
5.6.4. Patents
5.6.5. Technology
5.7. Inactive: Drug Profiles
5.7.1. Pre-Clinical Studies
5.7.2. Clinical Trials
5.7.3. Clinical Results
5.7.4. Strategic Developments
5.7.5. Designations
5.7.6. Grants
5.7.7. Patents
5.7.8. Technology
5.8. Discontinued: Drug Profiles
5.8.1. Pre-Clinical Studies
5.8.2. Clinical Trials
5.8.3. Clinical Results
5.8.4. Strategic Developments
5.8.5. Designations
5.8.6. Grants
5.8.7. Patents
5.8.8. Technology

6. Clinical Trials Analysis
6.1. Clinical Trials by Region
6.2. Clinical Trials by Trial Status

7. Competitive Landscape Analysis
7.1. Key Players Benchmarking
7.2. SWOT Analysis

8. Company Profiles
8.1 Business Overview
8.2 Product and Service Offerings

9. Appendix
9.1 Abbreviations

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Resverlogix Corp
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll